Journal of Parkinsons Disease

Papers
(The median citation count of Journal of Parkinsons Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline115
Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects107
Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations68
Parkinson’s Disease and the COVID-19 Pandemic67
Infection and Risk of Parkinson’s Disease62
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future62
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update60
Preventing Parkinson’s Disease: An Environmental Agenda56
Body-Worn Sensors for Remote Monitoring of Parkinson’s Disease Motor Symptoms: Vision, State of the Art, and Challenges Ahead53
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update45
Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis43
Global Perspective on Telemedicine for Parkinson’s Disease41
Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes41
Digital Therapeutics in Parkinson’s Disease: Practical Applications and Future Potential40
People with Parkinson’s Disease: What Symptoms Do They Most Want to Improve and How Does This Change with Disease Duration?39
Video-Based Analyses of Parkinson’s Disease Severity: A Brief Review38
Oral Dysbiosis and Inflammation in Parkinson’s Disease35
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)35
Proposal for a Biologic Staging System of Parkinson’s Disease35
Continuous Subcutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study34
Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts34
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOV33
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture32
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective32
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results31
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations31
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study31
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions30
Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson’s Disease: A Randomized Controlled Trial30
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update29
T Lymphocytes in Parkinson’s Disease29
A Practical Approach to Early-Onset Parkinsonism29
Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson’s Disease28
Does Gut Microbiota Influence the Course of Parkinson’s Disease? A 3-Year Prospective Exploratory Study in de novo Patients28
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion28
COVID-19 and Parkinson’s Disease: What Do We Know So Far?28
Genetics of Progressive Supranuclear Palsy: A Review27
A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial127
Fixation Duration and Pupil Size as Diagnostic Tools in Parkinson’s Disease27
Detection of Dermal Alpha-Synuclein Deposits as a Biomarker for Parkinson’s Disease26
Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction26
The Human Hippocampus in Parkinson’s Disease: An Integrative Stereological and Proteomic Study26
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease26
Microglia in Parkinson’s Disease26
Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses25
Slow Wave Sleep and EEG Delta Spectral Power are Associated with Cognitive Function in Parkinson’s Disease25
Quantitative Gait Analysis Using a Pose-Estimation Algorithm with a Single 2D-Video of Parkinson’s Disease Patients24
Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study24
A New Era: The Growth of Video-Based Visits for Remote Management of Persons with Parkinson’s Disease24
Barriers to Accessing Healthcare Services for People with Parkinson’s Disease: A Scoping Review24
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota23
Cannabis in Parkinson’s Disease: The Patients’ View23
Role of NLRP3 Inflammasome in Parkinson’s Disease and Therapeutic Considerations23
Effects of Cannabis in Parkinson’s Disease: A Systematic Review and Meta-Analysis23
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?22
Unhealthy Behaviours and Risk of Parkinson’s Disease: A Mendelian Randomisation Study22
COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?22
A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model21
Oral Health Disorders in Parkinson’s Disease: More than Meets the Eye21
Management of Sleep Disturbances in Parkinson’s Disease21
Non-Genetic Risk Factors for Parkinson’s Disease: An Overview of 46 Systematic Reviews21
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited21
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies21
Effectiveness of Long-Term Physiotherapy in Parkinson’s Disease: A Systematic Review and Meta-Analysis20
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease20
Lipidomics Prediction of Parkinson’s Disease Severity: A Machine-Learning Analysis20
Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson’s Disease Living in the United Kingdom20
An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function20
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population20
Effects of Helicobacter pylori on Levodopa Pharmacokinetics19
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials19
Comprehensive Analysis of Brain Volume in REM Sleep Behavior Disorder with Mild Cognitive Impairment19
Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson’s Disease?19
The Gut Mycobiome in Parkinson’s Disease19
Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers18
Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson’s Disease18
A Long Way to Go: Patient Perspectives on Digital Health for Parkinson’s Disease18
Reaching and Grasping Movements in Parkinson’s Disease: A Review17
CLOVER-DBS: Algorithm-Guided Deep Brain Stimulation-Programming Based on External Sensor Feedback Evaluated in a Prospective, Randomized, Crossover, Double-Blind, Two-Center Study17
Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes17
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients17
The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson’s Disease17
Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment16
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review16
A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson’s Disease: A Qualitative Study16
Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson’s Disease16
A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and Care16
Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson’s Disease16
Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease15
Dual-Task Costs of Quantitative Gait Parameters While Walking and Turning in People with Parkinson’s Disease: Beyond Gait Speed15
Plasma Short-Chain Fatty Acids Differences in Multiple System Atrophy from Parkinson’s Disease15
T Cells Limit Accumulation of Aggregate Pathology Following Intrastriatal Injection of α-Synuclein Fibrils15
Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis14
Diet Quality and Risk of Parkinson’s Disease: A Prospective Study and Meta-Analysis14
NEAT1 on the Field of Parkinson’s Disease: Offense, Defense, or a Player on the Bench?14
Decreased Risk of Parkinson’s Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls14
Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson’s Disease in the ICICLE-PD Cohort14
New Insights and Implications of Natural Killer Cells in Parkinson’s Disease14
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease14
Unraveling Parkinson’s Disease Neurodegeneration: Does Aging Hold the Clues?14
Effects of Resistance Training on Motor- and Non-Motor Symptoms in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis14
Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group14
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?13
Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease13
Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson’s Disease: A Regulatory Perspective13
Dopamine Cell Therapy: From Cell Replacement to Circuitry Repair13
Recruitment for Remote Decentralized Studies in Parkinson’s Disease13
Presence of Skin α-Synuclein Deposits Discriminates Parkinson’s Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome13
Worsened Parkinson’s Disease Progression: Impact of the COVID-19 Pandemic13
Incidence, Prevalence, and Mortality of Psychosis Associated with Parkinson’s Disease (1991–2010)13
Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study13
Body-First Subtype of Parkinson’s Disease with Probable REM-Sleep Behavior Disorder Is Associated with Non-Motor Dominant Phenotype13
Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men12
Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective12
Differentiating Parkinson’s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis12
Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex12
Smartphones for Remote Symptom Monitoring of Parkinson’s Disease12
Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review12
Inflammatory Animal Models of Parkinson’s Disease12
Short Pulse and Conventional Deep Brain Stimulation Equally Improve the Parkinsonian Gait Disorder12
How Time Rules: Diurnal Motor Patterns in de novo Parkinson’s Disease12
Life with Parkinson’s Disease During the COVID-19 Pandemic: The Pressure Is “OFF”12
Progression of Motor and Non-Motor Symptoms in Multiple System Atrophy: A Prospective Study from the Catalan-MSA Registry12
Frequency of Depressive Disorders in Parkinson’s Disease: A Systematic Review and Meta-Analysis12
Is there a Neurobiological Rationale for the Utility of the Iowa Gambling Task in Parkinson’s Disease?12
The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers11
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel11
Effects of a Highly Challenging Balance Training Program on Motor Function and Brain Structure in Parkinson’s Disease11
Association Between Thyroid Diseases and Parkinson’s Disease: A Nested Case-Control Study Using a National Health Screening Cohort11
Induction of Parkinsonian-Like Changes via Targeted Downregulation of Astrocytic Glutamate Transporter GLT-1 in the Striatum11
The Subjective Experience of Living with Parkinson’s Disease: A Meta-Ethnography of Qualitative Literature11
Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease11
Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease11
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up11
Irritable Bowel Syndrome and Risk of Parkinson’s Disease in Finland: A Nationwide Registry-Based Cohort Study11
Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity11
Parkinsonian Hand or Clinician’s Eye? Finger Tap Bradykinesia Interrater Reliability for 21 Movement Disorder Experts11
Inflammasome Activation in Parkinson’s Disease11
Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease10
Quantitative Digitography Measures Motor Symptoms and Disease Progression in Parkinson’s Disease10
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease10
Will Artificial Intelligence Replace the Movement Disorders Specialist for Diagnosing and Managing Parkinson’s Disease?10
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling10
Subthalamic Stimulation for Camptocormia in Parkinson’s Disease: Association of Volume of Tissue Activated and Structural Connectivity with Clinical Effectiveness10
Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson’s Disease10
B Lymphocytes in Parkinson’s Disease10
Respiratory Disorders in Parkinson’s Disease10
Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment10
Estimates of Intracellular Dopamine in Parkinson’s Disease: A Systematic Review and Meta-Analysis10
Structural and Functional Correlates of Hallucinations and Illusions in Parkinson’s Disease10
Self-Perception of Voice and Swallowing Handicap in Parkinson’s Disease10
Heart Rate Changes Prior to Freezing of Gait Episodes Are Related to Anxiety10
Locus Coeruleus Pathology Indicates a Continuum of Lewy Body Dementia10
Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson’s Disease10
The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy10
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder10
Mapping Relevance of Digital Measures to Meaningful Symptoms and Impacts in Early Parkinson’s Disease10
Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson’s Disease: Two Cases and Literature Review9
Peripheral Immune Cell Numbers and C-Reactive Protein in Parkinson’s Disease: Results from a Population-Based Study9
Delivering Multidisciplinary Rehabilitation Care in Parkinson’s Disease: An International Consensus Statement9
Whole Clinic Research Enrollment in Parkinson’s Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study9
Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale in Two Independent Cohorts with Early Parkinson’s Disease9
Parkinson’s Disease Cognitive Phenotypes Show Unique Clock Drawing Features when Measured with Digital Technology9
Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder9
Determinants of Self-Stigma in People with Parkinson’s Disease: A Mixed Methods Scoping Review9
Predicting Parkinson’s Disease and Its Pathology via Simple Clinical Variables9
Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action9
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson’s Disease9
Progressive Olfactory Impairment and Cardiac Sympathetic Denervation in REM Sleep Behavior Disorder9
Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity9
Negative Effects of COVID-19 Stay-at-Home Mandates on Physical Intervention Outcomes: A Preliminary Study9
Statins in Parkinson’s Disease: Influence on Motor Progression9
Parkinson’s Disease and the Gut Microbiome in Rural California9
Short and Long-Term Cognitive Effects of Subthalamic Deep Brain Stimulation in Parkinson’s Disease and Identification of Relevant Factors9
Autonomic and Depression Symptoms in Parkinson’s Disease: Clinical Evidence for Overlapping Physiology9
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring9
Blood Cholesterol Decreases as Parkinson’s Disease Develops and Progresses9
The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson’s Disease9
Phosphorylated α-Synuclein Deposits in Cutaneous Nerves of Early Parkinsonism9
Pedunculopontine and Cuneiform Nuclei Deep Brain Stimulation for Severe Gait and Balance Disorders in Parkinson’s Disease: Interim Results from a Randomized Double-Blind Clinical Trial9
REM Sleep Without Atonia and Gait Impairment in People with Mild-to-Moderate Parkinson’s Disease9
The Etiology of Parkinson’s Disease: New Perspectives from Gene-Environment Interactions9
Hypomimia May Influence the Facial Emotion Recognition Ability in Patients with Parkinson’s Disease9
Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease9
Blood Lipid Biomarkers in Early Parkinson’s Disease and Parkinson’s Disease with Mild Cognitive Impairment9
Neuroticism, Smoking, and the Risk of Parkinson’s Disease9
miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy9
Alcohol and Parkinson’s Disease: A Systematic Review and Meta-Analysis9
Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson’s Disease Mouse Model8
Domotics, Smart Homes, and Parkinson’s Disease8
Closed-Loop Adaptive Deep Brain Stimulation in Parkinson’s Disease: Procedures to Achieve It and Future Perspectives8
Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinson’s Disease: A Nationwide Cohort Study8
Relative Meaningfulness and Impacts of Symptoms in People with Early-Stage Parkinson’s Disease8
Neuroimaging Correlates of Substantia Nigra Hyperechogenicity in Parkinson’s Disease8
A Validation Study of PROMIS Sleep Disturbance (PROMIS-SD) and Sleep Related Impairment (PROMIS-SRI) Item Banks in Individuals with Idiopathic Parkinson’s Disease and Matched Controls8
An Evaluation of KELVIN, an Artificial Intelligence Platform, as an Objective Assessment of the MDS UPDRS Part III8
Impaired Weight-Shift Amplitude in People with Parkinson’s Disease with Freezing of Gait8
Age-Related Adaptive Immune Changes in Parkinson’s Disease8
Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis8
Integration of Virtual Reality into Transcranial Magnetic Stimulation Improves Cognitive Function in Patients with Parkinson’s Disease with Cognitive Impairment: A Proof-of-Concept Study8
Therapeutic Strategies for Immune Transformation in Parkinson’s Disease8
Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors8
Evidence-Based Aquatic Therapy Guidelines for Parkinson’s Disease: An International Consensus Study8
Slow Motion Analysis of Repetitive Tapping (SMART) Test: Measuring Bradykinesia in Recently Diagnosed Parkinson’s Disease and Idiopathic Anosmia8
Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson’s Disease Patients8
Immunogenetic Determinants of Parkinson’s Disease Etiology8
Cryopreservation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurospheres for Clinical Application8
A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System8
A Critical Analysis of Intestinal Enteric Neuron Loss and Constipation in Parkinson’s Disease8
Establishing Equivalent Aerobic Exercise Parameters Between Early-Stage Parkinson’s Disease and Pink1 Knockout Rats8
Epidemiological Evidence for an Immune Component of Parkinson’s Disease8
“No One Can Tell Me How Parkinson’s Disease Will Unfold”: A Mixed Methods Case Study on Palliative Care for People with Parkinson’s Disease and Their Family Caregivers8
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results8
Gender Distribution in Deep Brain Stimulation for Parkinson’s Disease: The Effect of Awake versus Asleep Surgery7
Cognitive Behavioral Therapy for Anxiety in Parkinson’s Disease Induces Functional Brain Changes7
Infusion Therapies in the Treatment of Parkinson’s Disease7
Combined Knockout of Lrrk2 and Rab29 Does Not Result in Behavioral Abnormalities in vivo7
Parkinson’s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success7
New Perspectives on Immune Involvement in Parkinson’s Disease Pathogenesis7
Relationship Between Brain Volumes and Objective Balance and Gait Measures in Parkinson’s Disease7
Stochastic Epigenetic Mutations Influence Parkinson’s Disease Risk, Progression, and Mortality7
The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson’s Disease7
The Experiences of Treatment Burden in People with Parkinson’s Disease and Their Caregivers: A Systematic Review of Qualitative Studies7
Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons7
Rate of Hospitalizations and Underlying Reasons Among People with Parkinson’s Disease: Population-Based Cohort Study in UK Primary Care7
Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study7
What Patients Say: Large-Scale Analyses of Replies to the Parkinson’s Disease Patient Report of Problems (PD-PROP)7
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression7
Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson’s Disease7
The Association Between REM Sleep Behavior Disorder and Autonomic Dysfunction in Parkinson’s Disease7
Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats7
Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms7
Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson’s Disease Severity7
Roles of Non-Coding RNAs as Novel Diagnostic Biomarkers in Parkinson’s Disease7
Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?7
Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits7
Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson’s Disease6
Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson’s Disease (PSYCHO-STIM II)6
Astrocytes and Alpha-Synuclein: Friend or Foe?6
A Multisensory Deficit in the Perception of Pleasantness in Parkinson’s Disease6
Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms6
Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials6
The Effects of Deep Brain Stimulation in Patients with Multiple System Atrophy6
The Role of Pathogens and Anti-Infective Agents in Parkinson’s Disease, from Etiology to Therapeutic Implications6
Clinical and Genetic Analysis of Psychosis in Parkinson’s Disease6
Telerehabilitation for Communication and Swallowing Disorders in Parkinson’s Disease6
Axial Impairment Following Deep Brain Stimulation in Parkinson’s Disease: A Surgicogenomic Approach6
Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson’s Disease6
Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson’s Disease Cohorts6
Rare Variants Analysis of Lysosomal Related Genes in Early-Onset and Familial Parkinson’s Disease in a Chinese Cohort6
0.04999303817749